Fully funded until mid-2022; raise would bolster tricaprilin development Tricaprilin commercial partner talks welcome in Phase III Alzheimer’s disease Cerecin…
BioEclipse Therapeutics will welcome CRO and CMO pitches from mid-2021 for its Phase II CRX100 trial in refractory solid tumours,…
Ripple Therapeutics is eyeing a $75m-plus initial public offering (IPO) in 2023, said CEO Tom Reeves. A company evaluation of…
Ridgeback Biotherapeutics/Merck’s Phase IIa molnupiravir is attractive for outpatient and recently hospitalised Covid-19 patients due to its mechanism and oral…
Mapi Pharma is working with the CRO PRA Health Sciences for its Phase III trial investigating glatiramer acetate depot (GA…
Revitope Oncology will be open to CRO and CMO pitches in a couple of months for a Phase I trial…
RenovoRx is receptive to investor pitches for an ongoing $10m-$20m Series C, which will fund the company up to an…
TG Therapeutics’ umbralisib monotherapy in relapsed/refractory (R/R) lymphomas is unlikely to have extensive market traction, experts said. The same sentiment…